GlassScriptPhysician profile
Matthew W Lorber
NPI 1730342726
$398,487.55
in general payments reported to CMS, 2019-2025
18 companies · $130K in 2025
The $130K reported for 2025 was more than what 99% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $69.28 · 2021: $759 · 2022: $4,665 · 2023: $123K · 2024: $140K · 2025: $130K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $214K · Honoraria: $112K · Travel and Lodging: $50K · Food and Beverage: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $213,865.00 |
| Honoraria | $112,046.00 |
| Travel and Lodging | $50,105.08 |
| Food and Beverage | $15,602.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $390,031.46 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $3,274.20 | 2024-2025 | Cobenfy |
| Corium, LLC | $1,557.93 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $991.19 | 2020-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $952.82 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $250.90 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $240.82 | 2022-2024 | Austedo Xr |
| Banner Life Sciences, LLC | $196.02 | 2021-2022 | |
| Nevro Corp. | $137.57 | 2021 | |
| Collegium Pharmaceutical, INC. | $134.28 | 2025 | Jornay Pm |
| Phathom Pharmaceuticals, INC. | $128.35 | 2024 | Voquezna |
| Abbvie INC. | $125.01 | 2025 | |
| Nalu Medical, INC. | $124.07 | 2025 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $108.88 | 2023 | |
| Supernus Pharmaceuticals, INC. | $92.31 | 2021-2024 | Qelbree |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $87.11 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $34.21 | 2020 | |
| Adlon Therapeutics L.P. | $20.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lorber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.